Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Total Current Liabilities (2020 - 2025)

SAB Biotherapeutics' Total Current Liabilities history spans 6 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 33.86% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, up 33.86%, while the annual FY2025 figure was $10.7 million, 33.86% up from the prior year.
  • Total Current Liabilities reached $10.7 million in Q4 2025 per SABSW's latest filing, down from $10.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $26.5 million in Q4 2021 to a low of $80000.0 in Q1 2021.
  • Average Total Current Liabilities over 5 years is $10.7 million, with a median of $10.7 million recorded in 2025.
  • Peak YoY movement for Total Current Liabilities: surged 23988.3% in 2022, then tumbled 46.14% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $26.5 million in 2021, then crashed by 43.33% to $15.0 million in 2022, then dropped by 27.88% to $10.8 million in 2023, then dropped by 26.21% to $8.0 million in 2024, then surged by 33.86% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Total Current Liabilities are $10.7 million (Q4 2025), $10.8 million (Q3 2025), and $10.7 million (Q2 2025).